Physician profile
Alfred H Kim
NPI 1124105234
$486,245.50
in general payments reported to CMS, 2019-2025
30 companies · $86K in 2025
The $86K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $40K · 2021: $54K · 2022: $148K · 2023: $76K · 2024: $67K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $87K · Consulting Fee: $85K · Travel and Lodging: $41K · Food and Beverage: $13K · Honoraria: $3,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,234.98 |
| Consulting Fee | $84,741.18 |
| Travel and Lodging | $40,582.81 |
| Food and Beverage | $13,125.08 |
| Honoraria | $3,674.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $361,068.78 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $27,768.38 | 2019-2025 | Cosentyx |
| Pfizer INC. | $21,028.47 | 2022-2025 | |
| Abbvie INC. | $20,650.81 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $11,797.64 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals Lp | $10,132.85 | 2021-2025 | Saphnelo, Evusheld |
| Janssen Scientific Affairs, LLC | $6,522.61 | 2023-2025 | Tremfya |
| Invivyd INC | $4,998.55 | 2025 | Pemgarda |
| Alexion Pharmaceuticals, INC. | $3,801.49 | 2020-2022 | |
| Amgen INC. | $2,987.78 | 2022-2025 | Tavneos, Uplizna |
| Biogen, INC. | $2,582.06 | 2025 | |
| Janssen Biotech, INC. | $2,539.81 | 2019-2025 | Tremfya, Simponi Aria |
| Ani Pharmaceuticals, INC. | $2,117.50 | 2022 | |
| Genentech USA, INC. | $1,915.00 | 2025 | Gazyva |
| E.R. Squibb & Sons, L.L.C. | $1,524.37 | 2023-2025 | Orencia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $1,343.00 | 2025 | |
| Genzyme Corporation | $968.48 | 2019-2025 | |
| Genentech, INC. | $592.16 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $588.81 | 2020-2025 | Acthar |
| Ucb, INC. | $319.52 | 2022-2023 | Cimzia |
| Lilly USA, LLC | $252.32 | 2021-2023 | Taltz |
| Mallinckrodt Enterprises LLC | $155.86 | 2019 | |
| Apellis Pharmaceuticals, INC. | $138.62 | 2025 | |
| Calliditas Therapeutics US INC. | $127.68 | 2023 | Tarpeyo |
| Sobi, INC | $116.77 | 2025 | |
| Horizon Therapeutics Plc | $92.42 | 2019-2022 | |
| Johnson & Johnson Health Care Systems INC. | $92.05 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $21.71 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.